---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-091820"
form_type: "8-K"
ticker: null
cik: "0001445283"
company_name: "KINETA, INC./DE"
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T09:56:38.892509+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TuHURA Biosciences completes acquisition of Kineta; Kineta stockholders get 0.185298 HURA shares each

## Summary
- Each Kineta share converted into 0.185298 shares of TuHURA common stock; ~2.87M HURA shares issued at close.
- 2nd contingent consideration: 1,129,885 additional HURA shares issuable after 6 months, subject to loss adjustments.
- Kineta VISTA mAb (KVA12123, now TBS-2025) added; Phase 2 trial in NPM1-mutated AML planned for H2 2025.
- Fourth tranche of $12.5M PIPE financing unlocked upon closing.
- Kineta stock halted on OTC Pink; company will file Form 15 to terminate SEC registration. All directors/officers resigned.

## SEC filing metadata
- accession: 0000950170-25-091820
- form_type: 8-K
- cik: 0001445283
- company_name: KINETA, INC./DE
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 3.03, 5.01, 5.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/0000950170-25-091820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/kant-20250630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-091820
- JSON: https://secwatch.observer/filing/0000950170-25-091820.json
- Plain text: https://secwatch.observer/filing/0000950170-25-091820.txt

## Key facts
- Governance Changes
  KINETA, INC./DE: Following merger, the Company's certificate of incorporation and bylaws were replaced by those of the surviving entity.
  - Change: charter amendment
  source text: Pursuant to the Merger Agreement, following the consummation of the Second Merger, the Company ceased to exist and Merger Sub II continued as the Surviving Company, and the organizational documents of Merger Sub II in effect immediately prior to the consummation of the Second Merger became the organizational documents of the Surviving Company (amended so that the name of the Surviving Company is Kineta, LLC).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/0000950170-25-091820-index.htm
- M&A Transactions
  KINETA, INC./DE completed an acquisition involving TuHURA Biosciences, Inc. for 0.185298 shares of TuHURA common stock per Kineta share, plus pro rata portion of 1,129,884 additional shares of TuHURA common stock after six months, and pro r (closed 2025-06-30).
  - Action: acquisition
  - Counterparty: TuHURA Biosciences, Inc.
  - Consideration: 0.185298 shares of TuHURA common stock per Kineta share, plus pro rata portion of 1,129,884 additional shares of TuHURA common stock after six months, and pro r
  - Closing: 2025-06-30
  source text: stock (each, a “Share”), par value $0.001 per share (“Kineta Common Stock”), issued and outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of TuHURA common stock, par value $0.001 per share (“TuHURA Common Stock”), for an aggregate of 2,868,168 shares of TuHURA Common Stock. Also pursuant to the terms and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/0000950170-25-091820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.